Avantra will identify biomarkers of interest, and MedTrust will engage oncologists in online discussions that will validate the role of different panels in diagnosis, prognosis, and treatment efficacy.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.